Abnormal increases of antiphospholipid antibody and plasma homocysteine levels are recently emerging as nonlipidic risk factors for cerebral atherogenesis and thrombosis. Both antiphospholipid antibody and homocysteine share many similar bioeffects in hemostasis, but their interaction is still inconsistent. In this study, we examined the relation between the plasma homocysteine level and lupus anticoagulant, anticardiolipin antibody, and anti-β 2glycoprotein I antibody in patients with noncardiac cerebral ischemia. Systemic lupus erythrematosus patients were excluded. The results showed a higher frequency of moderate hyperhomocysteinemia in patients with an abnormal increase of lupus anticoagulant only. Neither the serum folate and cobalamin levels nor methylenetetrahydrofolate reductase allele mutation contributes to this result. Accordingly, homocysteine interacts with lupus anticoagulant to promote cerebral atherosclerosis and ischemia. The role of vasculopathic or prothrombotic autoantibody generation in response to specific pathological change such as hyperhomocysteinemia warrants further investigation.
as an independent risk factor for cerebral ischemia and atherosclerosis (3) (4) (5) , irrespective of ethnicity. A 5 μM/L increase of the plasma homocysteine level raises the odds ratio from 1.10 to 2.16 for stroke (6) .
A similarity in endothelial cell dysfunction and procoagulation is observed between APAb and homocysteine. Both these could interfere with the protein C pathway, including the suppression of thrombomodulin synthesis and thrombin binding, the induction of activated protein C resistance, and the reduction of the protein C antigenic level or bioactivity. APAb and homocysteine also induce tissue factor expression, accelerating the coagulation cascade, (7) (8) (9) (10) and activating the nuclear factor κ-B. These analogies might interosculate to a common basis of coassociation between APAb and homocysteine. This proposal is reinforced when the odds ratio of hyperhomocysteinemia for cerebral ischemia increases from 2.16 in case-control studies of the general population (6) to 3.6 in APLS patients (11) . In this study, we examined the relationship between APAb and homocysteine to elucidate their interaction in cerebral ischemia patients.
The exact role of the nonlipidic cardiovascular risk factors, antiphospholipid antibody (APAb) and homocysteine, in atherogenesis and thrombosis has become clear recently. The family of APAbs, such as lupus anticoagulant (LAC), anticardiolipin antibody (aCL), and anti-β 2 -glycoprotein I antibody (aβGPI), is a constellation of autoantibodies reactive to the complex of anionic/neutral phospholipids and cofactor proteins. An abnormal increase of these autoantibodies has been shown to increase the risk of cerebral thrombosis and atherosclerosis in the general population (1) or in patients with systemic lupus erythrematosus (SLE) (2) or antiphospholipid antibody syndrome (APLS). Homocysteine is a thio-amino acid formed by demethylation of methionine. Hyperhomocysteinemia is advocated
MATERIALS AND METHODS

Population Sampling
A prospective study was conducted in our laboratory to investigate the role of autoantibody in the coagulation cascade in patients with noncardiac cerebral ischemia (NCCI). The clinical diagnosis of NCCI was adapted to our previous criteria (12, 13) . In brief, NCCI was diagnosed in patients with acute focal neurological deficit examined by 2 neurologists, with a corresponding infarct in the cranial computer tomography or magnetic resonance imaging findings reported by a neuroradiologist and an exclusion of cardiac disease based on the cardiac echogram and electrocardiogram results. In this study, further exclusions included the following: (a) a previous or current history of SLE, rheumatoid arthritis, or collagen disease; (b) a recent craniofacial trauma; (c) a consumption of herbal remedy, anticoagulant, estrogen, androgen, or corticosteroid; (d) a green tea drinking habit; (e) an abnormal renal (serum creatinine >1.2 mg/dL) or hepatic (serum glutamic oxaloacetic transaminase > 40 IU/L or cirrhosis) function; (f ) an abnormal thyroid or adrenal function; (g) a positive serum antinuclear factor ( >1:80); and (h) transient ischemic attack. The diagnosis of APLS was based on the International Consensus Statement on Preliminary Criteria for the Classification of the Antiphospholipid Syndrome. The reference range of aCL-IgG was <10 GPL/mL, and that for aCL-IgM was <6 MPL/mL, aβGPI <10 U/mL, and LAC > 1.2fold to the controls in our laboratory. The diagnosis of SLE was based on the criteria from the American College of Rheumatology with an updated revision.
Thirty healthy volunteers free of medical and neurological disorders were included as control. They were hospital employees, family of patients followed in the neurology clinic, or individuals asking for neurological examination.
Routine Laboratory Tests
The blood aCL, aβGPI, LAC, homocysteine, prothrombin time (PT), activated partial thromboplastin time (aPTT), complete blood count, total proteins, albumin, globulins, uric acid, aspartate aminotransferase, alanine aminotransferase, and creatinine were examined in each patient and healthy control. Venous blood was collected from the antecubital vein using a sterile vacutainer system after an overnight fasting for 10 hours. Blood was mixed with 3.8% trisodium citrate (1:9 citrate:blood). For aPTT, PT, homocysteine, aCL, aβGPI, and LAC, blood was centrifuged within 1 hour after collection (Universal 16R Hettich Zentrifgen) (for 10 minutes at 3000g at 4°C) to yield platelet-poor plasma. The aPTT and PT were done within 2 hours after collection. The platelet-poor plasma was aliquoted and stored at −20°C for batch measurement within 14 days. For the complete blood count, blood was examined within 4 hours by a Sysmex SE-9000 automated counter (Australian Diagnostics Corporation, Sydney, Australia). For total proteins, albumin, globulin, uric acid, aminotransferases, and creatinine, serum was examined within 2 hours after collection (Hitachi 7450 autoanalyzer, Tokyo, Japan) at room temperature.
Coagulation Tests, aCL, aβ βGPI, LAC, and Homocysteine
The PT and aPTT assays were performed on the Sysmex CA-6000 coagulometer (Australian Diagnostics Corporation). Thromboplastins used were APTT-LS (Fisher Diagnostics, Middletown, Va) for the aPTT and Innovin (Dade Behring Marburg GmbH, Marburg, Germany) for the PT. The ELISA method was used to measure the aCL-IgG, aCL-IgM, and aβGPI-IgG (Varelisa test kit, Pharmacia & Upjohn, Germany) (14) . LAC was determined by the mixing test and diluted Russell's viper venom test (LA Screen/LA Confirm, Gradipore Ltd, Australia). Homocysteine was measured using methods that have been licensed for commercial use (15) .
Analysis of the Methylenetetrahydrofolate Reductase Allele
The polymerase chain reaction primers for amplification of the methylenetetrahydrofolate reductase (MTHFR) mutation have been described elsewhere (16) . The primers generated a 198-bp fragment. The MTHFR polymorphism, a C-to-T substitution at bp 677, creates a HinfI recognition sequence. If the mutation is present, HinfI digests the 198-bp fragment into a 175-bp and a 23-bp fragment. The fragments were analyzed by polyacrylamide gel electrophoresis.
Statistical Analysis
Descriptive statistics for continuous variables were reported as mean and standard deviation. For categorical variables, number and percentage of patients were given. Differences between means were assessed with the least significant difference (LSD) test or 2-tailed Student t test for independent samples for variables with a normal distribution. Categorical variables were evaluated with the χ 2 test or Fisher exact test. A simple regression test was calculated between continuous variables to elucidate the correlation of each variable of a subset. A probability of less than .05 was considered significant.
RESULTS
There were a total of 181 patients, 127 men and 54 women, enrolled in this study. Their ages ranged from 28 to 84 years, with the average being 62.5 years. Hypertension was present in 122 patients, whereas diabetes mellitus was present in 62 patients. Among them, 116 patients (64.1%) had no APAb, whereas 65 (35.9%) patients had APAb; LAC was detected in 32 patients, aβGPI in 13, and aCL in 20. The serum total cholesterol, triglyceride, creatinine, uric acid, and hemoglobin levels showed no difference between these patients and controls ( Table 1 ). The mean PhL was 12. When the patients were further categorized according to their type of APAbs, the mean plasma homocysteine level was 12.1 ± 3.8, 13.4 ± 3.9, 11.8 ± 4.1, and 11.0 ± 2.8 μM/L in APAb(−), LAC(+), aβGPI(+), and aCL(+) patients, respectively (1-way ANOVA, F = 1.877, P = .135) ( Table 1) . A higher plasma homocysteine level was seen in LAC(+) patients than in aCL(+) patients (LSD, P = .024).
Twenty-four (20.7%) out of 116 APAb(−) patients and 17 (26.2%) out of 65 APAb(+) patients had moderate hyperhomocysteinemia (>15 μM/L) (χ 2 = 0.73, P > .1) ( Table 1 ). The frequency of moderate hyperhomocysteinemia was 20.7% in APAb(−), 40.6% in LAC(+), 23.1% in aβGPI(+), and 5.0% in aCL(+) patients (contingency table, t = 7.47, df = 3, P > .05). However, moderate hyperhomocysteinemia was more frequent in LAC(+) patients than in APAb(−) (χ 2 = 4.30, .05 > P > .025) or aCL(+) patients (χ 2 = 4.86, .05 > P > .025) but not in aβGPI(+) patients (Fisher exact test, P = .446). The serum cobalamin and folate levels did not differ in the LAC(+) or APAb(−) patients with or without hyperhomocysteinemia ( Table 2 ). Because hyperhomocysteinemia was present in only 1 aCL(+) and 3 aβGPI(+) patients, we did not compare their serum cobalamin and folate levels.
There was no linear correlation between the plasma homocysteine level and LAC activity in LAC(+) patients, the serum aβGPI level in aβGPI(+) patients, or the serum aCL level in aCL(+) patients.
The MTHFR allele was examined in all 65 APAb(+) patients. The frequency of heterozygote/ homozygote mutation in hyperhomocysteinemic LAC(+), aβGPI(+), and aCL(+) patients was 8 in 13, 1 in 3, and none in 1, respectively; however in normohomocysteinemic LAC(+), aβGPI(+), and aCL(+) patients, the frequency was 9 in 19, 4 in 10, and 8 in 19, respectively ( Table 2 ). The frequency of the MTHFR mutation did not differ among subgroups of APAbs. 
DISCUSSION
APAbs compete with the specific epitope within the phospholipid-protein complex on the cell surface and possess polygenicity on occasion. For example, the aCL, (17) aβGPI, (18, 19) or β 2 -glycoprotein I-dependent aCL (20) would exhibit LAC activity in vitro, or aβGPI would show a positive result similar to LAC in the diluted Russell's viper venom test (21) . These phenomena are because of a nonspecific competition on the phospholipid surface by APAbs, a low calcium level in a tested reagent, or multiple APAbs contemporarily. In this study, our patients were positive for 1 APAb only, and any interference in interpretation was minimized.
The frequency of hyperhomocysteinemia in our APAb(+) patients was 26.2%, which was similar to the value of 30.8% in a previous report (11) . Lopez et al (22) first reported a young man with venous thromboembolism having multiple coagulopathies including aCL, LAC, hyperhomocysteinemia, activated protein C resistance, and factor V Leiden mutation. Later, several studies concerning the correlation between homocysteine and APAb were conducted and produced inconsistent but closed results: hyperhomocysteinemia (23) or an insignificant trend toward a higher plasma homocysteine level (24) was found in APAb(+) patients rather than in APAb(−) patients or controls. In our series, this incongruity was still present until a higher frequency of hyperhomocysteinemia was identified in the LAC(+) patients. This selectively APAb-dependent hyperhomocysteinemia may explain the inconsistent results in previous studies when all subgroups of APAbs were included for investigation.
However, our result is not completely in agreement with the result of Fijnheer et al, (25) who did not find an interaction between LAC and homocysteine in 27 patients with a history of arterial thrombosis of 175 SLE patients. Frijns et al (26) also reported no difference in the plasma homocysteine level of thrombotic patients with and without LAC in the same series. Two points can be speculated. First, the underlying disease of their patients was SLE. The bioactivity of APAbs may be partially different among various diseases. For example, a decrease of protein C activity is observed in SLE patients, but there is an uncoupling of protein C and antithrombin III in non-SLE cerebral ischemia patients in association with an abnormal increase of blood aβGPI (27) . The LAC generated from different diseases may have distinct biospecificity in hemostasis (28) . Second, our patients suffered from cerebral ischemia, whereas in their patients, the arterial or venous thrombosis was in different vascular beds. The occurrence of thrombosis depends on the type of APAb and the vascular bed. For example, the odds ratio of cerebral thrombosis and coronary artery disease is 4.0 (29) and 2.0 (30) in increased aCL, respectively. Moreover, the odds ratio of hyperhomocysteinemia in APLS patients is 3.6 for cerebral ischemia but 6.0 for life-threatening thromboembolic events (11) .
A higher plasma homocysteine level was detected in concurrence with a MTHFR mutation and increased APAb than in a MTHFR mutation or increased APAb alone in previous studies (31) . A synergy of APAb and the MTHFR mutation is assumed for hyperhomocysteinemia in APAb(+) patients. However, the frequency of the MTHFR mutation did not differ between our LAC(+), aCL(+), and aβGPI(+) patients with hyperhomocysteinemia, suggesting that MTHFR mutation did not contribute to a higher frequency of hyperhomocysteinemia in our LAC(+) patients. Homocysteine is affected by factors such as lifestyle, diet, drugs, and a wide variety of clinical conditions and diseases. An impaired renal function is responsible for high hyperhomocysteinemia, whereas cobalamin and folate are the principal determinants for moderate hyperhomocysteinemia. The serum creatinine, cobalamin, and folate levels did not differ between our patients with or without hyperhomocysteinemia or between patients with either type of APAbs. Older age, male gender, hyperuricemia, and hemoconcentration are mentioned to be associated with a higher plasma homocysteine level, but they did not contribute to our series.
The cofactor protein bound with phospholipids for LAC generation is prothrombin, for aCL is cardiolipin, and for aβGPI is β 2 -glycoprotein I. There are no data to support whether homocysteine disturbs the phospholipids/prothrombin complex or vice versa. Homocysteine mainly exerts a cellular toxicity effect on the vascular system in 3 ways: protein homocysteinylation and homocysteine thiolactone formation, reduction of methylation, and oxidative/nitrosative stress (32) . These effects are dramatically enhanced by the low folate, low methionine, low high-density lipoprotein, and high homocysteine levels in the extracellular fluid. Homocysteinylation usually occurs at the side chain of the lysine residues in any plasma proteins as a result of structural change and loss of biological activity (33) . It has been known that derivatization of albumin, fibrinogen, or low-density lipoprotein cholesterol lysyl residues by carbamylation, acetylation, ethylation, or methylation would induce autoantibodies directed against these modifications in experimental animals. Homocysteinylated peptide provides a neoantigen to the body and creates an autoimmune response in humans (34, 35) . Moreover, a reduction of methylation would block the repair of the plasma proteins, cofactor proteins, and phospholipids that would result in neoantigen formation and autoimmune activation. The reason for a higher frequency of hyperhomocysteinemia in association with LAC than aCL or aβGPI is unknown. One possibility is that the kringle domain in prothrombin displays a stronger affinity to phospholipids on the cell surface than the complement control protein in aβGPI.
Our results show a subgroup specificity of APAb in association with hyperhomocysteinemia. This coassociative basis between LAC and homocysteine may intensify the risk of cerebral thrombosis and atherogenesis. On the other hand, this APAb-homocysteine relationship alerts one to any generation of other vasculopathic or prothrombotic autoantibody in other pathological conditions when plasma or cofactor protein is derivatized.
